Skip to main content

Table 2 Clinical characteristics of the stroke cohort

From: The negative impact of spasticity on the health-related quality of life of stroke survivors: a longitudinal cohort study

  All poststroke patients Patients with spasticity dataa Patients with spasticitya Patients without spasticitya P value*
N 460 328 54 274  
BMI, median (IQR) 27.4 (24.2–31.5) 27.9 (24.6–32.3) 28.1 (24.4–33.8) 27.9 (24.6–31.7) .50
Current smoker, n (%) 143 (31.0) 103 (31.0) 19 (35.0) 84 (31.0) .51
Comorbidities, n (%)
 Cardiovascular 201 (43.7) 134 (41.0) 20 (37.0) 114 (41.6) .53
 Diabetes 164 (35.6) 115 (35.0) 21 (38.9) 94 (34.3) .52
 Depression (CESD ≥10) 180 (39.2) 125 (38.0) 24 (44.4) 101(36.9) .29
 Seizure 30 (6.5) 20 (6.0) 8 (14.8) 12 (4.4) .01
 Infection 82 (17.9) 54 (17.0) 8 (14.8) 46 (16.8) .71
Prestroke Rankin (pre-mRS), median (IQR) 1 (0, 2) 1 (0, 2) 1 (0, 2) 1 (0, 2) .68
Lesion volume, median (IQR) N = 205 N = 143 N = 23 N = 120 .20
2 (0–14) 2 (0–16) 2 (1–39) 2 (0–12)
Estimated rNIHSS, median (IQR) 4 (2–7) 4 (2–7) 6 (3–10) 4 (2–6) .02
  1. Abbreviations: BMI body mass index, CESD Center for Epidemiologic Studies Depression scale, IQR interquartile range, mRS modified Rankin Scale, rNIHSS retrospective National Institute of Health Stroke Scale
  2. aAt 3 months
  3. *Comparison between patients with and without spasticity